Cure My Disease

Don't miss your cure!

 Log in / Sign up

Belly fat may hold key to ulcerative colitis treatment success

NCT ID NCT07126015

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether measuring visceral fat (belly fat) using CT scans can predict how well ulcerative colitis patients respond to biologic therapy. Researchers will follow 200 adults with active ulcerative colitis for 6 months, tracking changes in fat volume and treatment outcomes. The goal is to find a simple way to personalize treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which ulcerative colitis patients will benefit from biologic therapy, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not find a clear link between visceral fat and treatment response, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with ulcerative colitis will undergo detailed medical history (abdominal pain, bloody diarrhea frequency, tenesmus, mucus in stool), anthropometric measurements (weight, height, waist circumference, BMI), and physical examination for fever, tachycardia, abdominal tenderness, and weight loss. Disease activity will be assessed using Montreal classification, Harvey Bradshaw Index (HBI \< 5 = remission), and Truelove \& Witts criteria. Visceral adipose tissue volume and distribution will be evaluated by abdominal and pelvic CT examination.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any patient above age of 18 years old and diagnosed to have active UC through * Clinical features: rectal bleeding, with frequent stools and mucous discharge from the rectum. Some patients also describe tenesmus. The onset is typically insidious. * Endoscopic findings include the following; loss of vascular pattern, Granular and fragile mucosa, friability, ulcerations, erosions, pseudo-polyposis. Exclusion Criteria: * Patients with UC who are under age of 18 years old. * Pregnancy. * Previous colectomy. * Patient refuse to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Predicting biologics success via vat assessment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Predicting biologics success via vat assessment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.